Methadone Levels in Breast Milk of Women Taking Methadone for Opiate Addiction - 2
Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breast Feeding; Opioid-Related Disorders
Phase: N/A
Status: Completed
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s): Lauren M. Jansson, MD, Principal Investigator, Affiliation: Johns Hopkins University
Summary
Methadone is a drug that offers significant therapeutic benefits to opiate dependent women
who are pregnant. Currently, it is the treatment of choice for this group of people. The
purpose of this study is to determine the amount of methadone in the breast milk of women
who are breastfeeding and taking methadone for opiate addiction. In addition, this study
will evaluate the effects of methadone on infant neurobehavior.
Clinical Details
Official title: Breastfeeding Among Methadone Maintained Women
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: methadone concentrations in breast milkmethadone concentrations in maternal plasma
Secondary outcome: methadone concentrations in infant plasma
Detailed description:
Methadone is a drug that is commonly used to treat opiate addiction, usually as part of a
detoxification and maintenance program. Methadone offers significant therapeutic benefits
to pregnant women who are opiate dependent, and it is currently the treatment of choice for
this group of people. In general, breast milk is beneficial for infants. However, there is
some concern as to whether it is safe for women who are taking methadone to breastfeed their
babies. The purpose of this study is to determine the amount of methadone in the breast
milk of women who are breastfeeding and taking methadone for opiate addiction. In addition,
this study will evaluate the effects of methadone on infant neurobehavior.
Participants will be assigned to one of two groups: women taking methadone who will
breastfeed their babies or women taking methadone who will bottle-feed their babies. On
Days 1, 2, 3, 4, 14, and 30, following infant delivery, plasma will be collected from both
groups and breast milk will be collected from the breastfeeding group. These samples will
be quantitatively analyzed for methadone. Infants will undergo neurobehavioral assessments
on Days 3, 14, and 30, following birth. Rates and severity of neonatal abstinence syndrome
will also be evaluated.
Eligibility
Minimum age: 18 Years.
Maximum age: 40 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Generally healthy methadone-maintained women electing to either exclusively
breastfeed or bottle-feed their infants for 1 month after delivery
Exclusion Criteria:
- Relapse to illicit drugs or alcohol at any time during the study
- Positive maternal or infant urine toxicology test at birth
- Serious medical or psychiatric illness requiring medication or medical intervention
- HIV infected
- Currently dependent on alcohol
- Major birth defect in the infant
- Significant medical problems in the infant, including premature birth, sepsis, or
other infections
Locations and Contacts
Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland 21224 6823, United States
Additional Information
Related publications: Jansson LM, Velez M, Harrow C. Methadone maintenance and lactation: a review of the literature and current management guidelines. J Hum Lact. 2004 Feb;20(1):62-71. Review.
Starting date: November 2000
Last updated: April 15, 2015
|